Logo of Neurotech International (ASX:NTI)Latest Neurotech International (ASX:NTI) News

Page 2
Page 2 of 4

Healthcare Wrap - Week 29 (13 July -> 17 July) 2026

Big price swings hit healthcare stocks this week, but the sharpest falls did not always match the news flow. Revenue growth, trial progress and fresh US deals kept buying interest alive across parts of the sector.
Logan Eniac
18 July 2026

Neurotech Secures $3.15 Million Loan Backed by R&D Tax Incentives for Phase III Trials

Neurotech International has locked in a $3.15 million secured loan against its anticipated R&D tax incentives to fund pivotal Phase III autism trials and ongoing operations.
Ada Torres
15 July 2026

US FDA Clears IND for Neurotech’s NTI164, Paving Way for US Trials

Neurotech International has secured FDA clearance for its Investigational New Drug application for NTI164, enabling clinical development in the US and advancing its global registration and commercialisation plans.
Ada Torres
14 July 2026

Healthcare Wrap - Week 27 (29 June -> 3 July) 2026

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.
Logan Eniac
4 July 2026

Neurotech Secures US Patent Allowances for NTI164, Extending Protection to 2042

Neurotech International has received Notices of Allowance from the USPTO for two patents covering its lead drug NTI164, reinforcing its intellectual property position as it advances Phase 3 trials for autism spectrum disorder.
Ada Torres
2 July 2026

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.
Logan Eniac
2 May 2026

Neurotech Advances Phase 3 Autism Trial and Reports Strong Safety Data for NTI164

Neurotech International has opened its first Phase 3 clinical site for NTI164 targeting Autism Spectrum Disorder, reported positive 90-day toxicology results, and launched a new Rett syndrome research collaboration.
Ada Torres
29 Apr 2026

Market Wrap - Week 12 (16 Mar -> 20 Mar) 2026

A brutal split opened up in small caps: a few stocks surged on hard approvals and funding, while many resource names slid even after announcing big numbers. The week’s tape looked simple: investors paid for certainty and sold anything that still needs time, permits, or more cash.
Logan Eniac
21 Mar 2026

Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.
Logan Eniac
21 Mar 2026

Neurotech Launches Phase 3 Trial Site for Autism Treatment NTI164

Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.
Ada Torres
17 Mar 2026

Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.
Logan Eniac
28 Feb 2026

Neurotech Slashes Loss, Advances NTI164 with Key Trials and Funding Boost

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.
Ada Torres
26 Feb 2026